Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Resistance-associated epitopes of HIV-1C-highly probable candidates for a multi-epitope vaccine.

Sundaramurthi JC, Swaminathan S, Hanna LE.

Immunogenetics. 2012 Oct;64(10):767-72. doi: 10.1007/s00251-012-0635-z. Epub 2012 Jul 19.

PMID:
22810271
2.

HLA-B*27:05-specific cytotoxic T lymphocyte epitopes in Indian HIV type 1C.

Sundaramurthi JC, Ramanathan VD, Hanna LE.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):47-53. doi: 10.1089/AID.2011.0374. Epub 2012 Oct 15.

PMID:
22924625
3.

For protection from HIV-1 infection, more might not be better: a systematic analysis of HIV Gag epitopes of two alleles associated with different outcomes of HIV-1 infection.

Luo M, Daniuk CA, Diallo TO, Capina RE, Kimani J, Wachihi C, Kimani M, Bielawny T, Peterson T, Mendoza MG, Kiazyk S, Ball TB, Plummer FA.

J Virol. 2012 Jan;86(2):1166-80. doi: 10.1128/JVI.05721-11. Epub 2011 Nov 9.

4.

The effect of HLA polymorphisms on the recognition of Gag epitopes in HIV-1 CRF01_AE infection.

Sriwanthana B, Mori M, Tanaka M, Nishimura S, Miura T, Pathipvanich P, Sawanpanyalert P, Ariyoshi K.

PLoS One. 2012;7(7):e41696. doi: 10.1371/journal.pone.0041696. Epub 2012 Jul 27. Erratum in: PLoS One. 2014;9(8):e106978.

5.

Sequence analysis of HIV-1 isolates from Guinea-Bissau: selection of vaccine epitopes relevant in both West African and European countries.

Vinner L, Holmgren B, Jensen KJ, Esbjornsson J, Borggren M, Hentze JL, Karlsson I, Andresen BS, Gram GJ, Kloverpris H, Aaby P, Da Silva ZJ, Fenyö EM, Fomsgaard A.

APMIS. 2011 Aug;119(8):487-97. doi: 10.1111/j.1600-0463.2011.02763.x. Epub 2011 May 14.

PMID:
21749448
6.

Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1.

Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, Crimi C, Southwood S, Sette A, Chesnut R, Newman MJ, Livingston BD.

J Immunol. 2003 Nov 15;171(10):5611-23.

7.

Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa.

Masemola AM, Mashishi TN, Khoury G, Bredell H, Paximadis M, Mathebula T, Barkhan D, Puren A, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, Karim SA, Sheppard HW, Gray CM; HIVNET 028 Study Team.

J Immunol. 2004 Oct 1;173(7):4607-17.

8.

Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele.

Ferrari G, Neal W, Ottinger J, Jones AM, Edwards BH, Goepfert P, Betts MR, Koup RA, Buchbinder S, McElrath MJ, Tartaglia J, Weinhold KJ.

J Immunol. 2004 Aug 1;173(3):2126-33.

9.

Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.

De Groot AS, Bishop EA, Khan B, Lally M, Marcon L, Franco J, Mayer KH, Carpenter CC, Martin W.

Methods. 2004 Dec;34(4):476-87.

PMID:
15542374
10.

Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach.

De Groot AS, Jesdale B, Martin W, Saint Aubin C, Sbai H, Bosma A, Lieberman J, Skowron G, Mansourati F, Mayer KH.

Vaccine. 2003 Oct 1;21(27-30):4486-504.

PMID:
14505932
11.
12.

Design of a HIV-1-derived HLA-B07.02-restricted polyepitope construct.

Cardinaud S, Bouziat R, Rohrlich PS, Tourdot S, Weiss L, Langlade-Demoyen P, Burgevin A, Fiorentino S, van Endert P, Lemonnier FA.

AIDS. 2009 Sep 24;23(15):1945-54. doi: 10.1097/QAD.0b013e32832fae88.

PMID:
19644347
13.

Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic.

Schellens IM, Navis M, van Deutekom HW, Boeser-Nunnink B, Berkhout B, Kootstra N, Miedema F, Keşmir C, Schuitemaker H, van Baarle D, Borghans JA.

AIDS. 2011 Sep 10;25(14):1691-700. doi: 10.1097/QAD.0b013e32834981b3.

PMID:
21681058
14.

Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA.

Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, Pillay T, Hilton L, Thobakgale C, Ramduth D, Draenert R, Le Gall S, Luzzi G, Edwards A, Brander C, Sewell AK, Moore S, Mullins J, Moore C, Mallal S, Bhardwaj N, Yusim K, Phillips R, Klenerman P, Korber B, Kiepiela P, Walker B, Goulder P.

J Exp Med. 2005 Mar 21;201(6):891-902.

15.

Immune responses induced in HHD mice by multiepitope HIV vaccine based on cryptic epitope modification.

Li Y, Huang Y, Liang J, Xu Z, Shen Y, Zhang N, Liu Z, Zhao Y.

Mol Biol Rep. 2013 Apr;40(4):2781-7. doi: 10.1007/s11033-012-2202-y. Epub 2013 Mar 1.

PMID:
23456642
16.

HIV-1-specific cytotoxic T lymphocyte (CTL) responses against immunodominant optimal epitopes slow the progression of AIDS in China.

Zhai S, Zhuang Y, Song Y, Li S, Huang D, Kang W, Li X, Liao Q, Liu Y, Zhao Z, Lu Y, Sun Y.

Curr HIV Res. 2008 Jun;6(4):335-50.

PMID:
18691032
17.

HIV/AIDS. HLA leaves its footprints on HIV.

McMichael A, Klenerman P.

Science. 2002 May 24;296(5572):1410-1. No abstract available.

PMID:
12029119
18.

Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine.

Rosa DS, Ribeiro SP, Fonseca SG, Almeida RR, Santana VC, Apostólico Jde S, Kalil J, Cunha-Neto E.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1077-88. doi: 10.1089/AID.2015.0101. Epub 2015 Aug 13. Review.

PMID:
26149745
19.

Evaluation of peptide selection approaches for epitope-based vaccine design.

Schubert B, Lund O, Nielsen M.

Tissue Antigens. 2013 Oct;82(4):243-51. doi: 10.1111/tan.12199.

PMID:
24461003
20.

Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53.

Dorrell L, Willcox BE, Jones EY, Gillespie G, Njai H, Sabally S, Jaye A, DeGleria K, Rostron T, Lepin E, McMichael A, Whittle H, Rowland-Jones S.

Eur J Immunol. 2001 Jun;31(6):1747-56.

Items per page

Supplemental Content

Write to the Help Desk